Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Launched by NOVO NORDISK A/S ·
Trial Information
Current as of September 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is a follow-up study that focuses on the safety of a drug called INV-347, which was given to participants in an earlier study for obesity. The main goal is to check how the drug affected the body over time by looking at blood levels and overall safety. Importantly, no new doses of the drug will be given during this study. It will last about two years to carefully monitor participants’ health.
People who took part in the original INV-347 study and are between the ages of 65 and 74 may be eligible to join this follow-up. Both men and women can participate. During the study, participants will have regular check-ups and blood tests to make sure the drug did not cause any lasting problems. This study is currently recruiting volunteers, and it helps researchers understand the long-term safety of INV-347 for people with obesity.
Gender
ALL
Eligibility criteria
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported